Microbial Metabolite-Mediated α-Synuclein Disaggregation
Target: SNCA, HSPA1A, DNMT1
Composite Score: 0.511
Price: $0.51▲44.8%
Citation Quality: Pending
neurodegeneration
Status: proposed
🟢 Parkinson's Disease 🔥 Neuroinflammation 🔮 Lysosomal / Autophagy 🔴 Alzheimer's Disease 🟡 ALS / Motor Neuron Disease 🧠 Neurodegeneration
✓ All Quality Gates Passed
Quality Report Card click to collapse
C+
Composite: 0.511
Top 73% of 1374 hypotheses
T5 Contested
Contradicted by evidence, under dispute
D
0.30
Top 97%
C
0.40
Top 82%
A
0.80
Top 25%
C+
0.50
Top 62%
B
0.60
Top 62%
C
0.40
Top 77%
B+
0.70
Top 23%
B
0.60
Top 61%
C
0.40
Top 86%
D
0.30
Top 93%
Evidence
5 supporting
|
0 opposing
Citation quality: 100%
Debates
1 session
A
Avg quality: 0.89
Convergence
1.00
A+
30 related hypothesis share this target
From Analysis:
What are the mechanisms underlying what are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis?
Hypotheses from Same Analysis (6)
These hypotheses emerged from the same multi-agent debate that produced this hypothesis.
Microbial Inflammasome Priming Prevention
Score: 0.653 | Target: NLRP3, CASP1, IL1B, PYCARD
Vagal Afferent Microbial Signal Modulation
Score: 0.621 | Target: GLP1R, BDNF
Gut Barrier Permeability-α-Synuclein Axis Modulation
Score: 0.533 | Target: CLDN1, OCLN, ZO1, MLCK
Enteric Nervous System Prion-Like Propagation Blockade
Score: 0.480 | Target: TLR4, SNCA
Microbiome-Derived Tryptophan Metabolite Neuroprotection
Score: 0.427 | Target: AHR, IL10, TGFB1
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.384 | Target: TH, AADC
Description
Specific gut bacterial strains produce short-chain fatty acids (SCFAs) that cross the blood-brain barrier and directly modulate α-synuclein aggregation through epigenetic modifications of chaperone proteins. Therapeutic supplementation with SCFA-producing bacteria could prevent or reverse pathological protein aggregation in PD.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
graph TD
A["Gut Microbiome
B. longum, F. prausnitzii
A. muciniphila"] --> B["SCFA Production
Butyrate, Propionate
Acetate"]
B --> C["Blood-Brain Barrier
Crossing via MCT1/MCT2
Transporters"]
C --> D["HDAC Inhibition
HDAC1, HDAC3, HDAC6
Suppression"]
D --> E["Histone Hyperacetylation
H3/H4 Acetylation
Chromatin Remodeling"]
E --> F["HSF1/NF-Y Transcription
Factor Activation"]
F --> G["HSPA1A Upregulation
Heat Shock Protein 70
Expression"]
C --> H["DNMT1 Inhibition
DNA Methylation
Reduction"]
H --> I["Neuroprotective Gene
Demethylation"]
G --> J["Enhanced Protein
Chaperone Activity"]
I --> J
J --> K["alpha-Synuclein
Disaggregation"]
L["alpha-Synuclein
Pathological Aggregates"] --> K
K --> M["Reduced Neuronal
Toxicity"]
M --> N["Neuroprotection
Disease Modification"]
O["Therapeutic Intervention
SCFA Supplementation
Probiotic Administration"] --> B
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
5 citations
5 with PMID
5 medium
Validation: 100%
5 supporting / 0 opposing
✓
For
(5)
(0)
Against
✗
High
Medium
Low
High
Medium
Low
Evidence Matrix
— sortable by strength/year, click Abstract to expand
Evidence Types
MECH 1CLIN 4GENE 0EPID 0
Legacy Card View — expandable citation cards
✓ Supporting Evidence 5
Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease. MEDIUM
Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models. MEDIUM
A ROS-Responsive nanoparticle for nuclear gene delivery and autophagy restoration in Parkinson's disease thera… MEDIUM▼
A ROS-Responsive nanoparticle for nuclear gene delivery and autophagy restoration in Parkinson's disease therapy.
Preclinical Alzheimer's disease shows alterations in circulating neuronal-derived extracellular vesicle microR… MEDIUM▼
Preclinical Alzheimer's disease shows alterations in circulating neuronal-derived extracellular vesicle microRNAs in a multiethnic cohort.
The Crosstalk Between Sepsis-Associated Encephalopathy and Alzheimer's Disease: Identifying Potential Biomarke… MEDIUM▼
The Crosstalk Between Sepsis-Associated Encephalopathy and Alzheimer's Disease: Identifying Potential Biomarkers and Therapeutic Targets for Cognition.
✗ Opposing Evidence 0
No evidence recorded
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 6 rounds | 2026-04-01 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼
Based on the provided literature on the gut-brain axis and Parkinson's disease, here are 7 novel therapeutic hypotheses:
1. Microbial Metabolite-Mediated α-Synuclein Disaggregation
Description: Specific gut bacterial strains produce short-chain fatty acids (SCFAs) that cross the blood-brain barrier and directly modulate α-synuclein aggregation through epigenetic modifications of chaperone proteins. Therapeutic supplementation with SCFA-producing bacteria could prevent or reverse pathological protein aggregation in PD.
Target gene/protein: SNCA (α-synuclein), HSPA1A (HSP70), DNMT1
🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼
I'll provide a rigorous critique of each hypothesis, identifying key weaknesses and gaps in the evidence.
1. Microbial Metabolite-Mediated α-Synuclein Disaggregation
Critical Weaknesses:
- Mechanistic gap: No direct evidence that SCFAs can disaggregate α-synuclein in vivo. The leap from "SCFAs affect epigenetics" to "SCFAs disaggregate α-synuclein" lacks mechanistic validation.
- Blood-brain barrier assumptions: While some SCFAs cross the BBB, their concentrations and stability in brain tissue remain poorly characterized.
- Chaperone specificity: No evidence that SCFA-medi
🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼
REFINED DRUG DEVELOPMENT FEASIBILITY ASSESSMENT
Based on the additional data retrieved, I'm updating my feasibility rankings with concrete evidence from current research and clinical pipelines.
UPDATED HYPOTHESIS RANKINGS
1. NLRP3 Inflammasome Inhibition (Hypothesis #6)
Feasibility Score: 8/10 ⬆️ Upgraded based on new clinical dataKey Development Update:
- NT-0796 (PMID:40792655, 2025) showing anti-neuroinflammatory effects specifically in PD subjects
- KPT-8602 (PMID:35721113) demonstrating NF-κB/NLRP3 pathway inhibition in PD models
**Immediate Opportunities:
⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼
Price History
7d Trend
↔
Stable
7d Momentum
▼ 0.8%
Volatility
Low
0.0133
Events (7d)
6
⚡ Price Movement Log
Recent 15 events
| Event | Price | Change | Source | Time | |
|---|---|---|---|---|---|
| 📄 | New Evidence | $0.469 | ▲ 1.2% | evidence_batch_update | 2026-04-13 02:18 |
| 📄 | New Evidence | $0.464 | ▲ 3.5% | evidence_batch_update | 2026-04-13 02:18 |
| ⚖ | Recalibrated | $0.448 | ▼ 0.5% | 2026-04-12 10:15 | |
| ⚖ | Recalibrated | $0.450 | ▼ 1.2% | 2026-04-10 15:58 | |
| ⚖ | Recalibrated | $0.456 | ▲ 1.5% | 2026-04-10 15:53 | |
| ⚖ | Recalibrated | $0.449 | ▼ 3.8% | 2026-04-08 18:39 | |
| ⚖ | Recalibrated | $0.467 | ▼ 12.9% | 2026-04-06 04:04 | |
| ⚖ | Recalibrated | $0.536 | ▼ 0.6% | 2026-04-04 16:38 | |
| ⚖ | Recalibrated | $0.539 | ▼ 0.4% | 2026-04-04 16:02 | |
| 📄 | New Evidence | $0.542 | ▲ 0.7% | evidence_batch_update | 2026-04-04 09:08 |
| ⚖ | Recalibrated | $0.538 | ▼ 2.0% | 2026-04-03 23:46 | |
| ⚖ | Recalibrated | $0.549 | ▼ 5.6% | 2026-04-02 21:55 | |
| 💬 | Debate Round | $0.581 | ▲ 34.1% | market_dynamics | 2026-04-02 19:41 |
| ⚖ | Recalibrated | $0.433 | ▼ 2.5% | market_recalibrate | 2026-04-02 19:14 |
| 📄 | New Evidence | $0.444 | ▼ 41.2% | market_dynamics_seed | 2026-04-02 18:16 |
Clinical Trials (5) Relevance: 44%
0
Active
Active
0
Completed
Completed
282
Total Enrolled
Total Enrolled
PHASE1
Highest Phase
Highest Phase
RAPA-501 Therapy for ALS
PHASE2
RECRUITING
·
NCT04220190 · Rapa Therapeutics LLC
41 enrolled · 2025-01-02 · → 2026-07-01
RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).
Amyotrophic Lateral Sclerosis
RAPA-501 Autologous T stem cells
COMPLETED
·
NCT03955380 · Prof. Dr. Dieter Willbold
24 enrolled · 2018-12-12 · → 2019-04-03
This is a single-center multiple-ascending-dose clinical trial assessing the safety and tolerability of oral dosing of Contraloid acetate in healthy volunteers. The study drug Contraloid (alias RD2, a
Alzheimer Dementia Alzheimer Disease
Contraloid
UNKNOWN
·
NCT04820881 · Washington D.C. Veterans Affairs Medical Center
60 enrolled · 2021-10-01 · → 2024-09
This grant award entitled, "Cerebrovascular Reactivity and Oxygen Metabolism as Markers for Neurodegeneration after Traumatic Brain Injury" (hereafter, "Neurovascular Study"), aims to determine if neu
Neurodegenerative Diseases
Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's Disease
PHASE1
NOT_YET_RECRUITING
·
NCT07212088 · iCamuno Biotherapeutics Ltd.
12 enrolled · 2026-02-28 · → 2027-12-15
Parkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain. Current drug treatments p
Parkinson Disease
ALC01 therapy
COMPLETED
·
NCT02405182 · University of Alberta
145 enrolled · 2014-09 · → 2019-03
Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Increasing age is an important risk f
Amyotrophic Lateral Sclerosis ALS Motor Neuron Diseases
Magnetic Resonance Imaging
📚 Cited Papers (37)
Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.
Movement disorders : official journal of the Movement Disorder Society (2017) · PMID:29124790
1 figure
Figures
Figures available at source paper (no open-access XML found).
deep_link
Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy: implications for Parkinson disease.
Autophagy (2020) · PMID:30966861
1 figure
Figures
Figures available at source paper (no open-access XML found).
deep_link
Alpha-synuclein, Parkinson's disease, and Alzheimer's disease.
Parkinsonism & related disorders (2004) · PMID:15109581
No extracted figures yet
Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.
Movement disorders : official journal of the Movement Disorder Society (2017) · PMID:29124790
No extracted figures yet
Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy: implications for Parkinson disease.
Autophagy (2020) · PMID:30966861
No extracted figures yet
Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson's Disease.
Neuron (2019) · PMID:31255487
No extracted figures yet
Kv1.3 modulates neuroinflammation and neurodegeneration in Parkinson's disease.
J Clin Invest (2020) · PMID:32597830
No extracted figures yet
Mitochondria and Parkinson's Disease: Clinical, Molecular, and Translational Aspects.
Journal of Parkinson's disease (2021) · PMID:33074190
No extracted figures yet
The Role of α-Synuclein Oligomers in Parkinson's Disease.
International journal of molecular sciences (2020) · PMID:33212758
No extracted figures yet
Mitochondrial Dysfunction and Mitophagy in Parkinson's Disease: From Mechanism to Therapy.
Trends in biochemical sciences (2021) · PMID:33323315
No extracted figures yet
The role of neuroimaging in Parkinson's disease.
J Neurochem (2021) · PMID:34532856
No extracted figures yet
Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease.
Acta pharmaceutica Sinica. B (2021) · PMID:34729301
No extracted figures yet
📙 Related Wiki Pages (15)
NES Protein proteinPBKR03 entitySNCA — Alpha-Synuclein geneDNMT1 Gene geneHSPA1A Gene geneHSPA1A Protein proteinSNCA — Alpha-Synuclein Gene Entity Page geneExosome Therapy for Neurodegeneration therapeuticArcuate NPY Neurons in Neurodegeneration cellPhotoreceptors in Neurodegeneration cellEconomic Burden — Neurodegeneration diseaseGlucocorticoid Signaling Pathway in Neurodegenerat mechanismLipid Raft Dysfunction in Neurodegeneration mechanismRaphe Serotonergic Neurons in Neurodegeneration cellPET Imaging in Neurodegeneration diagnostic
📓 Linked Notebooks (5)
📓 SciDEX Analysis: 2026 04 01 Gap 20260401 225155
Computational notebook for SDA-2026-04-01-gap-20260401-225155
📓 What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis? — Rich Analysis
Enhanced notebook with gene expression, pathway enrichment, score heatmaps, and statistical analysis. What are the mechanisms underlying what are the mechanisms by which gut microbiome dysbiosis influ …
📓 Gut microbiome dysbiosis and Parkinsons disease -- Rich Analysis Notebook
Gene expression, pathway enrichment, statistical tests for: Gut microbiome dysbiosis and Parkinsons disease
📓 What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis?
What are the mechanisms underlying what are the mechanisms by which gut microbiome dysbiosis influences parkinson's disease pathogenesis through the gut-brain axis??
📓 What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis?
What are the mechanisms underlying what are the mechanisms by which gut microbiome dysbiosis influences parkinson's disease pathogenesis through the gut-brain axis??
Wiki Pages
NES ProteinproteinPBKR03entitySNCA — Alpha-SynucleingeneDNMT1 GenegeneHSPA1A GenegeneHSPA1A ProteinproteinSNCA — Alpha-Synuclein Gene Entity PagegeneExosome Therapy for NeurodegenerationtherapeuticArcuate NPY Neurons in NeurodegenerationcellPhotoreceptors in NeurodegenerationcellEconomic Burden — NeurodegenerationdiseaseGlucocorticoid Signaling Pathway in NeurodegeneratmechanismLipid Raft Dysfunction in NeurodegenerationmechanismRaphe Serotonergic Neurons in NeurodegenerationcellPET Imaging in Neurodegenerationdiagnostic
KG Entities (12)
GLP1_receptorNLRP3Parkinsons_diseaseSCFA_productionblood_brain_barriergut_microbiomeinflammasome_complexintestinal_barrierneuroinflammation_pathwayneuroprotectiontight_junction_proteinsvagal_signaling_pathway
Dependency Graph (7 upstream, 1 downstream)
Depends On
Enteric Nervous System Prion-Like Propagation Blockadebuilds_on (1.0)Smartphone-Detected Motor Variability Correctionbuilds_on (1.0)Gut Barrier Permeability-α-Synuclein Axis Modulationbuilds_on (1.0)Noradrenergic-Tau Propagation Blockadebuilds_on (1.0)Cross-Seeding Prevention Strategybuilds_on (1.0)Low Complexity Domain Cross-Linking Inhibitionbuilds_on (0.6)Mitochondrial Transfer Pathway Enhancementbuilds_on (0.6)Linked Experiments (10)
Iron Dyshomeostasis in MSA Pathogenesis Experimentvalidation | tests | 0.40Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiation Mechanismsclinical | tests | 0.40Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechanism and Interventionclinical | tests | 0.40Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propagationclinical | tests | 0.40Stress Granule Dysfunction Validation in Parkinson's Diseaseclinical | tests | 0.40Tau Co-Pathology in DLB Clinical Heterogeneityclinical | tests | 0.40Prodromal Parkinson's Disease Biomarker Development — Early Detection for Prevenclinical | tests | 0.40Alpha-Synuclein SAA Kinetics Study — Biological Staging Backbone for PD Progressclinical | tests | 0.40Parkinson's Disease Subtype Classification — Precision Medicine Approachclinical | tests | 0.40Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleationvalidation | tests | 0.40
Related Hypotheses
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration
Score: 0.990 | neurodegeneration
TREM2-Dependent Microglial Senescence Transition
Score: 0.950 | neurodegeneration
PLCG2 Allosteric Modulation as a Precision Therapeutic for TREM2-Dependent Microglial Dysfunction
Score: 0.941 | neurodegeneration
Multi-Biomarker Composite Index Surpassing Amyloid PET for Treatment Response Prediction
Score: 0.933 | neurodegeneration
CYP46A1 Gene Therapy for Age-Related TREM2-Mediated Microglial Senescence Reversal
Score: 0.921 | neurodegeneration
Estimated Development
Estimated Cost
$0
Timeline
2.2 years
🧪 Falsifiable Predictions (2)
2 total
0 confirmed
0 falsified
If hypothesis is true, intervention incorporate engineered bacterial strains with enhanced SCFA production capacity and targeted delivery mechanisms, including synthetic biology approaches to optimize butyrate biosynthetic pathways
pending
conf: 0.40
Expected outcome: incorporate engineered bacterial strains with enhanced SCFA production capacity and targeted delivery mechanisms, including synthetic biology approaches to optimize butyrate biosynthetic pathways
Falsified by: Intervention fails to incorporate engineered bacterial strains with enhanced SCFA production capacity and targeted delivery mechanisms, including synthetic biology approaches to optimize butyrate biosynthetic pathways
If hypothesis is true, intervention integrate pharmacogenomic profiling, microbiome analysis, and metabolomic signatures to optimize strain selection and dosing for individual patients
pending
conf: 0.40
Expected outcome: integrate pharmacogenomic profiling, microbiome analysis, and metabolomic signatures to optimize strain selection and dosing for individual patients
Falsified by: Intervention fails to integrate pharmacogenomic profiling, microbiome analysis, and metabolomic signatures to optimize strain selection and dosing for individual patients
Knowledge Subgraph (7 edges)
associated with (2)
contributes to (1)
encodes component (1)
maintains (1)
mediates (1)
promotes (1)
Mechanism Pathway for SNCA, HSPA1A, DNMT1
Molecular pathway showing key causal relationships underlying this hypothesis
graph TD
NLRP3["NLRP3"] -->|encodes component| inflammasome_complex["inflammasome_complex"]
neuroinflammation_pathway["neuroinflammation_pathway"] -->|contributes to| Parkinsons_disease["Parkinsons_disease"]
GLP1_receptor["GLP1_receptor"] -->|mediates| vagal_signaling_pathway["vagal_signaling_pathway"]
vagal_signaling_pathway_1["vagal_signaling_pathway"] -->|promotes| neuroprotection["neuroprotection"]
tight_junction_proteins["tight_junction_proteins"] -->|maintains| intestinal_barrier["intestinal_barrier"]
gut_microbiome["gut_microbiome"] -->|associated with| SCFA_production["SCFA_production"]
SCFA_production_2["SCFA_production"] -->|associated with| blood_brain_barrier["blood_brain_barrier"]
style NLRP3 fill:#ce93d8,stroke:#333,color:#000
style inflammasome_complex fill:#4fc3f7,stroke:#333,color:#000
style neuroinflammation_pathway fill:#81c784,stroke:#333,color:#000
style Parkinsons_disease fill:#ef5350,stroke:#333,color:#000
style GLP1_receptor fill:#4fc3f7,stroke:#333,color:#000
style vagal_signaling_pathway fill:#81c784,stroke:#333,color:#000
style vagal_signaling_pathway_1 fill:#81c784,stroke:#333,color:#000
style neuroprotection fill:#ffd54f,stroke:#333,color:#000
style tight_junction_proteins fill:#4fc3f7,stroke:#333,color:#000
style intestinal_barrier fill:#4fc3f7,stroke:#333,color:#000
style gut_microbiome fill:#4fc3f7,stroke:#333,color:#000
style SCFA_production fill:#4fc3f7,stroke:#333,color:#000
style SCFA_production_2 fill:#4fc3f7,stroke:#333,color:#000
style blood_brain_barrier fill:#4fc3f7,stroke:#333,color:#000
3D Protein Structure
🧬 SNCA — PDB 1XQ8 Click to expand 3D viewer
Source Analysis
What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis?
neurodegeneration | 2026-04-01 | completed
Community Feedback
0
0 upvotes · 0 downvotes
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!